KEYMED BIOSCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.4 HKD | +5.85% |
|
+1.62% | -29.94% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,864 | 12,600 | 12,348 | 8,835 | - | - |
| Enterprise Value (EV) 1 | 4,378 | 12,118 | 11,517 | 7,702 | 7,253 | 7,561 |
| P/E ratio | -1.16 x | -38.2 x | -32.6 x | -10.7 x | -11.3 x | -19.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 71.3 x | 126 x | 34.9 x | 79.3 x | 16.6 x | 7.15 x |
| EV / Revenue | 39.7 x | 121 x | 32.5 x | 69.2 x | 13.7 x | 6.12 x |
| EV / EBITDA | -10.9 x | -46.8 x | -42.7 x | -9.64 x | -9.78 x | -14.1 x |
| EV / FCF | -11.3 x | -17.8 x | -18.3 x | -8.03 x | -8.72 x | -10.8 x |
| FCF Yield | -8.83% | -5.62% | -5.48% | -12.5% | -11.5% | -9.28% |
| Price to Book | 2.15 x | 3.74 x | 4.13 x | 4.02 x | 5.78 x | 5.67 x |
| Nbr of stocks (in thousands) | 279,736 | 279,736 | 276,696 | 276,604 | - | - |
| Reference price 2 | 28.11 | 45.04 | 44.63 | 31.94 | 31.94 | 31.94 |
| Announcement Date | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 110.3 | 100.1 | 354.1 | 111.4 | 531.3 | 1,236 |
| EBITDA 1 | - | -402.3 | -259.1 | -269.8 | -798.7 | -741.9 | -537.7 |
| EBIT 1 | - | -415.2 | -544.5 | -457.4 | -834.6 | -773.7 | -499.4 |
| Operating Margin | - | -376.55% | -544.15% | -129.18% | -749.49% | -145.64% | -40.4% |
| Earnings before Tax (EBT) 1 | -818.8 | -3,893 | -303.6 | -356.2 | -820.3 | -781.4 | -473.2 |
| Net income 1 | -818.6 | -3,887 | -308.1 | -359.4 | -822 | -782.7 | -467.5 |
| Net margin | - | -3,525.3% | -307.92% | -101.49% | -738.1% | -147.34% | -37.82% |
| EPS 2 | - | -24.17 | -1.180 | -1.370 | -2.976 | -2.823 | -1.668 |
| Free Cash Flow 1 | - | -386.4 | -680.8 | -630.8 | -959.4 | -832 | -701.4 |
| FCF margin | - | -350.44% | -680.33% | -178.15% | -861.54% | -156.61% | -56.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 6/25/21 | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 3,485 | 482 | 832 | 1,133 | 1,582 | 1,275 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -386 | -681 | -631 | -959 | -832 | -701 |
| ROE (net income / shareholders' equity) | - | -22.7% | -8.81% | -11.4% | -34.8% | -49.5% | -47.1% |
| ROA (Net income/ Total Assets) | - | -13% | -7.83% | - | -24.6% | -26.8% | -16.3% |
| Assets 1 | - | 29,902 | 3,933 | - | 3,342 | 2,921 | 2,875 |
| Book Value Per Share 2 | - | 13.10 | 12.00 | 10.80 | 7.950 | 5.530 | 5.640 |
| Cash Flow per Share 2 | - | -1.330 | -1.540 | -1.160 | -1.560 | -1.000 | 1.660 |
| Capex 1 | - | 172 | 279 | 327 | 201 | 101 | 99.4 |
| Capex / Sales | - | 155.79% | 278.65% | 92.4% | 180.19% | 18.95% | 8.04% |
| Announcement Date | 6/25/21 | 3/29/22 | 3/17/23 | 3/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
31.94
CNY
Average target price
53.6
CNY
Spread / Average Target
+67.81%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.94% | 1.22B | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- 2162 Stock
- Financials Keymed Biosciences Inc.
